Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control

Area of Science:

• Immunology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes (T2D) involves immune dysregulation and inflammation.
• Cytokine imbalance is linked to T2D progression and severity.

Purpose of the Study:

• To review the antihyperglycemic effects of disease-modifying antirheumatic drugs (DMARDs) and anticytokine agents.
• To explore the molecular mechanisms and clinical rationale for using anticytokine therapies in T2D.
• To summarize experimental and clinical evidence on anticytokine therapies for T2D.

Main Methods:

• Literature review of existing evidence on DMARDs and specific anticytokine agents (anti-TNF-α, anti-IL-6, anti-IL-1, anti-IL-17, anti-IL-23).
• Analysis of molecular mechanisms and biological rationale for T2D treatment.
• Summary of findings from experimental models and clinical trials.

Main Results:

• Anticytokine agents demonstrate potential antihyperglycemic properties.
• These therapies impact systemic and islet inflammation, beta-cell function, insulin secretion, and insulin sensitivity.
• Promising results from preclinical and clinical studies indicate therapeutic potential.

Conclusions:

• Anticytokine therapies represent a potential additional treatment strategy for type 2 diabetes.
• Targeting cytokine dysregulation offers a novel approach to managing T2D.
• Further clinical investigation is warranted to establish the efficacy and safety of these agents in T2D management.